ANG Lifesciences India News

ANG Lifesciences FY26 results

ANG Lifesciences reported a consolidated loss of ₹1,108.48 lakh for FY26, narrowing from ₹1,241.33 lakh in FY25. Revenue rose to ₹9,289.28 lakh.

ANG Lifesciences Board Meeting on May 30

ANG Lifesciences India Limited has scheduled a board meeting on May 30, 2026, to consider the audited financial results for Q4 and FY26.

ANG Lifesciences confirms non-applicability of LC rules

ANG Lifesciences India Limited disclosed to BSE that it does not fall under the Large Corporate category for FY26, making SEBI borrowing requirements non-applicable to the company.

ANG Lifesciences Submits Q4 FY26 SEBI Compliance Certificate

ANG Lifesciences India Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4 FY26 ended March 31, 2026, confirming proper dematerialization processes through its registrar Bigshare Services.

ANG Lifesciences clarifies price movement to BSE

ANG Lifesciences India Limited responds to BSE inquiry on recent price movement, stating no price-sensitive information exists and movement is purely market-driven.